MARKET

CMMB

CMMB

Chemomab Therapeutics Ltd
NASDAQ

Real-time Quotes | Nasdaq Last Sale

12.40
-0.20
-1.59%
After Hours: 12.50 +0.1 +0.81% 19:57 09/16 EDT
OPEN
12.56
PREV CLOSE
12.60
HIGH
12.78
LOW
12.20
VOLUME
35.34K
TURNOVER
--
52 WEEK HIGH
168.80
52 WEEK LOW
11.30
MARKET CAP
136.44M
P/E (TTM)
-0.2627
1D
5D
1M
3M
1Y
5Y
BRIEF-Chemomab Therapeutics Announces Appointment Of Dale Pfost As Chief Executive Officer
reuters.com · 09/02 11:32
Chemomab Therapeutics Announces Appointment of Dale Pfost as Chief Executive Officer
/PRNewswire/ -- . (Nasdaq: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for inflammatory and fibrotic diseases with high unmet need, today announced it has appointed , PhD, as Chief Executive O...
PR Newswire - PRF · 09/02 11:00
Chemomab Therapeutics Names Dale Pfost Chief Executive
MT Newswires · 09/02 08:14
Chemomab to Participate in Upcoming September Investor Conferences
Chemomab Therapeutics, Ltd. (Nasdaq: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need, today announced that the Company will participate in the fo...
PR Newswire · 09/01 11:18
60 Biggest Movers From Yesterday
Gainers Vinco Ventures, Inc. (NASDAQ: BBIG) shares rose 80.9% to close at $5.30 on Friday. The company recently reported a Q2 loss of $5.13 per share.
Benzinga · 08/30 09:18
BRIEF-Chemomab Therapeutics Announces Q2 Results
reuters.com · 08/13 12:29
Chemomab Therapeutics Q2 EPS $(0.01), Same YoY
Chemomab Therapeutics (NASDAQ:CMMB) reported quarterly losses of $(0.01) per share. This is unchanged from the same period last year.
Benzinga · 08/13 12:04
Chemomab Therapeutics Announces Second Quarter 2021 Financial Results and Provides a Business Update
/PRNewswire/ -- . (Nasdaq: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need, today announced financial and operating results for the second quarte...
PR Newswire - PRF · 08/13 12:00
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CMMB. Analyze the recent business situations of Chemomab Therapeutics Ltd through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CMMB stock price target is 43.50 with a high estimate of 45.00 and a low estimate of 42.00.
EPS
Institutional Holdings
Institutions: 16
Institutional Holdings: 3.38M
% Owned: 30.71%
Shares Outstanding: 11.00M
TypeInstitutionsShares
Increased
1
32.35K
New
5
398.67K
Decreased
4
8.06K
Sold Out
4
227.41K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.83%
Pharmaceuticals & Medical Research
+0.11%
Key Executives
Non-Executive Chairman/Independent Director
Stephen Squinto
Chief Executive Officer/Chief Scientific Officer/Director
Adi Mor
Chief Financial Officer
Sigal Fattal
Other
Aaron Aharon
Independent Director
Neil Cohen
Independent Director
Nissim Darvish
Independent Director
Joel Maryles
Independent Director
Alan Moses
Independent Director
Claude Nicaise
No Data
About CMMB
Chemomab Therapeutics Ltd, formerly known as Anchiano Therapeutics Ltd, is a Israel-based biopharmaceutical company. The Company specializes in the development of patient oriented targeted therapy for the treatment of a wide range of cancers. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.

Webull offers kinds of Chemomab Therapeutics Ltd - ADR stock information, including NASDAQ:CMMB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CMMB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CMMB stock methods without spending real money on the virtual paper trading platform.